2. Signaling Pathways
  3. Immunology/Inflammation
  4. Complement System

Complement System

Complement System

Related Products

PDF 0.66 MB

The complement system, composed of more than 30 serum and cell surface components, is collaborating in recognition and elimination of pathogens as a part of both the innate and acquired immune systems. Once the complement system is activated, a chain of reactions involving proteolysis and assembly occurs, resulting in cleavage of the third complement component (C3). The cascade up to C3 cleavage is called the activation pathway. There are three activation pathways: the classical, lectin, and alternative pathways.

The complement cascade is a dual-edged sword, causing protection against bacterial and viral invasion by promoting phagocytosis and inflammation. Pathologically, complement can cause substantial damage to blood vessels (vasculitis), kidney basement membrane and attached endothelial and epithelial cells (nephritis), joint synovium (arthritis), and erythrocytes (hemolysis) if it is not adequately controlled.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P10274
    CM05
    		Inhibitor
    CM05 is a bromo-fatty acid. CM05 can be used to modify ornithodoros moubata complement inhibitor (OmCI) and extend the half-life of OmCI.
    CM05
  • HY-P10788
    CK3 peptide
    		Inhibitor
    CK3 peptide is an NRP-1 targeting peptide with the amino acid sequence CLKADKAKC. The CK3 peptide specifically binds to NRP-1 to target breast cancer cells. Single-photon emission computed tomography (SPECT) and near-infrared fluorescence (NIRF) imaging show significant accumulation of CK3 peptide in xenograft tumors in nude mice. CK3 peptide can be used for molecular imaging studies of breast cancer.
    CK3 peptide
  • HY-P990745
    Izastobart
    		Ligand
    Izastobart is an anti-C5AR1 human IgG1 λ2 monoclonal antibody. Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096).
    Izastobart
  • HY-N10400
    Campneoside II
    		Inhibitor
    Campneoside II is a compound isolated from Paulownia tomentosa var. tomentosa wood. Campneoside II exhibits excellent anti-complement activity.
    Campneoside II
  • HY-147606
    Factor B-IN-4
    		Inhibitor
    Factor B-IN-4 (Example 13 target compound) is a potent complement factor B inhibitor, with an IC50 of 1 μM. Factor B-IN-4 can be used for the research of diseases related to inflammation and immunity.
    Factor B-IN-4
  • HY-163378
    C5aR1 antagonist 1
    		Antagonist
    C5aR1 antagonist 1 (Compound 7e) is an orally active C5a receptor 1 (C5aR1) antagonist. C5aR1 antagonist 1 is active in DISCO and migration assays, with IC50 values of 38 nM and 17 nM, respectively. C5aR1 antagonist 1 can be used for the research of acute and chronic inflammatory diseases.
    C5aR1 antagonist 1
  • HY-P1640
    (Trp63,Trp64)​-​C3a(63-77)
    		Agonist
    (Trp63,Trp64)​-​C3a(63-77) is a C3a synthetic analogue peptide, which exhibits Ca2+ stimulating efficacy in human neutrophils and hC3aR or mC3aR expressing RBL-2H3 cells with EC50 of 9.5, 2.0 and 0.8 nM, respectively.
    (Trp63,Trp64)​-​C3a(63-77)
  • HY-P4971
    C5a Anaphylatoxin (human)
    		Modulator
    C5a Anaphylatoxin (human) is a pro-inflammatory peptide and a leukocyte chemoattractant. C5a Anaphylatoxin (human) can be used to study inflammation and immunity, such as allergic asthma.
    C5a Anaphylatoxin (human)
  • HY-P3502A
    Zilucoplan TFA
    		Inhibitor
    Zilucoplan TFA (RA101495), a 15-amino acid macrocyclic peptide, is a potent complement component 5 (C5) inhibitor. Zilucoplan TFA can be used in research of immune-mediated necrotising myopathy (IMNM).
    Zilucoplan TFA
  • HY-P10827
    PIC1 PA
    		Inhibitor
    PIC1 PA, a 15 amino-acid peptide, is a potent PIC1 analog that inhibits classical pathway mediated complement activation. PIC1 PA functionally disrupts the C1s-C1r-C1r-C1s/MASPs interaction with collagen-like region (CLR) of C1q/MBL, respectively. PIC1 PA specifically binds to the CLR of C1q and bounds to purified C1q with a mean equilibrium dissociation constant (KD) of 33.3 nM.
    PIC1 PA
  • HY-P3204A
    POT-4 TFA
    		Inhibitor
    POT-4 TFA (AL-78898A TFA), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 TFA can be used for age-related macular degeneration research.
    POT-4 TFA
  • HY-P10787
    tLyP-1 peptide
    		Inhibitor
    tLyP-1 peptide is an NRP-1 targeting peptide with an IC50 of 4 μM, and its amino acid sequence is CGNKRTR. tLyP-1 peptide specifically binds to NRP-1 to target tumor cells.
    tLyP-1 peptide
  • HY-147585
    C5aR-IN-1
    C5aR-IN-1 is a potent inhibitor of C5aR. Increased level of C5a has been associated with disorders such as autoimmune disorders and inflammatory disorders. C5aR-IN-1 has the potential for the research of inflammation diseases (extracted from patent WO2022028586A1, compound 47).
    C5aR-IN-1
  • HY-14648S2
    Dexamethasone-d4
    		Inhibitor
    Dexamethasone-d4 is deuterium labeled Dexamethasone. Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes. Dexamethasone is highly effective in the control of COVID-19 infection. Dexamethasone inhibits production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses.
    Dexamethasone-d<sub>4</sub>
  • HY-W371164
    C1s-IN-1
    		Inhibitor
    C1s-IN-1 (compound A1) is a selective and competitive inhibitor of C1s. C1s-IN-1 binds directly to C1s with a Kd of 9.8 μM.
    C1s-IN-1
  • HY-147587
    C5aR-IN-3
    C5aR-IN-3 is a potent inhibitor of C5aR. Increased level of C5a has been associated with disorders such as autoimmune disorders and inflammatory disorders. C5aR-IN-3 has the potential for the research of inflammation diseases (extracted from patent WO2022028586A1, compound 89).
    C5aR-IN-3
  • HY-P1345
    TLQP-21
    		Agonist
    TLQP-21, a VGF-derived peptide endowed of endocrine and extraendocrine properties, is a potent G-protein-coupled receptor complement-3a receptor 1 (C3aR1) agonist (EC50: mouse TLQP-21=10.3 μM; human TLQP-21=68.8 μM). TLQP-21 activates C3aR1 to induce an increase of intracellular Ca2+. TLQP-21 is used for the research in regulation of nociception and other relevant physiologic functions.
    TLQP-21
  • HY-E70534
    C1s Proenzyme
    C1s Proenzyme, the native form of C1s enzyme, is an inactive zymogen until C1 is activated. C1 complex binds to and is activated by antigen-antibody complexes (immune complexes) yielding C1r enzyme. C1r enzyme in the C1 complex activates C1s proenzyme generating C1s enzyme.
    C1s Proenzyme
  • HY-130043
    11-O-Methylpseurotin A
    11-O-Methylpseurotin A is a compound of mixed polyketide synthase–nonribosomal peptide synthetase (PKS/NRPS) origin. 11-O-Methylpseurotin A selectively inhibits a Hof1 deletion strain.
    11-O-Methylpseurotin A
  • HY-P990844
    Anti-GC1q R/C1QBP Antibody (60.11)
    		Inhibitor
    Anti-GC1q R/C1QBP Antibody (60.11) is a kind of mouse IgG1, κ chimeric antibody, targeting to human GC1q R/C1QBP. The recommend isotype control of Anti-GC1q R/C1QBP Antibody (60.11): Mouse IgG1 kappa, Isotype Control (HY-P99977).
    Anti-GC1q R/C1QBP Antibody (60.11)
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity